Author: Alumis Inc.

Posted Date:

March 28, 2026

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis Inc.

March 28, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Inc.

March 20, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis Inc.

March 18, 2026
Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis Inc.

March 2, 2026
Alumis to Participate in Upcoming February Investor Conferences

Alumis Inc.

February 7, 2026